Adjuvant S-1 Chemotherapy Bests Gemcitabine in Asian Patients With Pancreatic Cancer

Friday, January 25, 2013

Adjuvant chemotherapy with the oral fluoropyrimidine S-1 improved survival versus standard postoperative gemcitabine in Asian patients with pancreatic cancer, according to an interim analysis from a phase III trial conducted in Japan. The data were presented at a press briefing ahead of the 2013 Gastrointestinal Cancers Symposium, held from January 24-26 in San Francisco, California…

Source:
Onclive.com